Here's one reason why experts think the CSL share price can rise 65%!

MotleyFool03-26 05:00

The CSL Ltd (ASX: CSL) share price has taken a dive over the last several months. As the chart below shows, it has fallen almost 50% from August 2025. But, experts think there's a chance that the ASX ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622007554?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 05:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622007554","market":"hk","top_or_hot":-1,"title":"Here's one reason why experts think the CSL share price can rise 65%!","media":"MotleyFool","content":"<div>\n<p>The CSL Ltd (ASX: CSL) share price has taken a dive over the last several months. As the chart below shows, it has fallen almost 50% from August 2025. But, experts think there's a chance that the ASX ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/26/heres-one-reason-why-experts-think-the-csl-share-price-can-rise-65/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's one reason why experts think the CSL share price can rise 65%!</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's one reason why experts think the CSL share price can rise 65%!\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-26 05:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2026/03/26/heres-one-reason-why-experts-think-the-csl-share-price-can-rise-65/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The CSL Ltd (ASX: CSL) share price has taken a dive over the last several months. As the chart below shows, it has fallen almost 50% from August 2025. But, experts think there's a chance that the ASX ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/26/heres-one-reason-why-experts-think-the-csl-share-price-can-rise-65/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64QTZ34.USD","symbol_name":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","start_time":0,"source_url":"https://www.fool.com.au/2026/03/26/heres-one-reason-why-experts-think-the-csl-share-price-can-rise-65/","article_id":"2622007554","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/26/heres-one-reason-why-experts-think-the-csl-share-price-can-rise-65/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622007554","pubTimestamp":1774472400,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"The CSL Ltd  share price has taken a dive over the last several months. As the chart below shows, it has fallen almost 50% from August 2025. But, experts think there's a chance that the ASX healthcare share could recover a lot of the lost ground.The global biotech business provides a number of healthcare products, including blood plasma-related treatments and vaccines.UBS recently released a note that outlined one of the reasons why investors can be excited by the business.The broker said that there has been a rapid uptake of CSL's Andembry since the launch in mid-2025, with more than 1,000 patients on the therapy. UBS estimates this is around 15% of patients on prophylactic treatment across the major markets where it has been approved.At a US price of around $400,000, the broker said this early momentum should underpin \"strong second-half FY26 sales and extend into FY27\".UBS suggests that its hereditary angioedema  forecasts may prove conservative, as it has allowed for competitive pr","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK7511":"ESG概念","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","BK4588":"碎股","LU1863844665.USD":"TEMPLETON EUROLAND \"A\" (USD) ACC A","HAE":"美国血液技术","BK7067":"生物科技","IE0034235071.USD":"PINEBRIDGE EUROPE RESEARCH ENHANCED EQUITY \"A\" (USD) ACC","LU3187612489.SGD":"TEMPLETON EUROPEAN INSIGHTS \"A\" (SGDHDG) ACC","BK7501":"新冠治疗股","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","CSL.AU":"CSL LIMITED","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","UBS":"瑞银","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","BK4198":"医疗保健用品","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU1863844749.USD":"TEMPLETON EUROLAND \"A\" (USD) INC","BK7508":"医药生物股","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","BK4118":"综合性资本市场","CSL":"卡莱尔伙伴","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4086":"建筑产品"},"translate_title":"这就是专家认为CSL股价可以上涨65%的原因之一！","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5,"CSL.AU":1.5,"HAE":1,"UBS":0.9},"content_text":"The CSL Ltd (ASX: CSL) share price has taken a dive over the last several months. As the chart below shows, it has fallen almost 50% from August 2025. But, experts think there's a chance that the ASX healthcare share could recover a lot of the lost ground.\n\nThe global biotech business provides a number of healthcare products, including blood plasma-related treatments and vaccines.\nUBS recently released a note that outlined one of the reasons why investors can be excited by the business.\nImage source: Getty Images\nUBS is positive on the biotech giant\nThe broker said that there has been a rapid uptake of CSL's Andembry since the launch in mid-2025, with more than 1,000 patients on the therapy. UBS estimates this is around 15% of patients on prophylactic treatment across the major markets where it has been approved.\nAt a US price of around $400,000, the broker said this early momentum should underpin \"strong second-half FY26 sales and extend into FY27\".\nUBS suggests that its hereditary angioedema (HAE) forecasts may prove conservative, as it has allowed for competitive pressure in its projections and therefore expects CSL's HAE market share to peak in FY27.\nThe broker is projecting that CSL's market share could rise from around 20% in FY25 to a peak of 27% in FY27. UBS said its cautious stance reflects \"gradual switching from incumbent therapies, including Haegarda, and competition from other new therapies, both approved and currently in clinical trials.\"\nUBS believes there's \"meaningful upside if Andembry takes more\" market share.\nThe broker said its scenario analysis suggests the FY30 (estimated) earnings could get a 9% potential boost if CSL lifts its market share to 40% of the global HAE market. While ambitious, UBS said that possible outcome is \"credible given Andembry's clear advantages in convenience and patient experience\".\nUBS also noted that CSL's long history with this patient group positions it well to take share from the market leader, Takeda.\nIs the CSL share price a buy?\nThe broker is still bullish on the business, despite the market's pessimism.\nUBS currently has a buy rating on the business, with a price target of $235. A price target tells investors where they think the share price will be in a year from the time of the investment call. The broker's price target suggests a possible rise of 66% over the next year. \nThe broker projects that the business could generate net profit of US$3.4 billion in FY26.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622007554","isCrawlerRequest":true}